Allergan's Trivaris approved to treat retinal diseases
Allergan, Trivaris, retinal diseases, vision loss, ocular
Trivaris (triamcinolone acetonide injectable suspension) 80 mg/mL is a new anti-inflammatory drug from Allergan to treat retinal diseases that can result in vision loss. A synthetic glucocorticoid corticosteroid, the product is an intravitreal shot that treats sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. The Irvine, Calif., firm said the introduction marks its first product for back-of-the-eye diseases.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.
